Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial.

Topics include:

1. Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug conjugate (ADC)
2. Future direction of ADC treatments

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly

Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial.

Topics include:

1. Neoadjuvant vepdegestrant: results of TACTIVE-N trial
2. Tolerance in next-generation endocrine therapies: PROTAC estrogen receptor degraders

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly

Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial.

Topics include:

1. Mechanisms of resistance to CDK4/6 inhibitors
2. Rationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohort

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly

Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy.

Topics include:

1. Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancer
2. Treatment persistence during real-world adjuvant CDK4/6 inhibitor therapy

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly

Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer.

Topics include:

1. Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrence
2. Balancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatment

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly

Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer.

Topics include:

1. The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancer
2. Long-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trial

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly